All News
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 randomised controlled trials in Sjogren's disease (iscalimab, ianalumab, dazodalibep, and sequential therapy belimumab + rituximab). Since many previous studies have shown the discordance between physician assessment and patient’s symptom burden, there is a glimmer of hope with the efficacy signals demonstrated by both iscalimab and dazodalibep in two patient cohorts; a) cohort 1 = high disease activity with variable symptom burden and b) cohort 2 = high symptom burden but low disease activity. EULAR 2024 offered additional updates.
Read Article
EULAR 2024 – Day 4 Report
The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action.
Read Article
Choices in GCA
There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.
Read Article
Difficult-to-treat RA: are we any closer to predicting who is at risk?
It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Peter Nash drpnash ( View Tweet)
